Clinical and Pathological Correlations in Chronic Venous Disease. 2022

Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
Interuniversity Center of Phlebolymphology (CIFL). International Research and Educational Program in Clinical and Experimental Biotechnology" at the Department of Surgical and Medical Sciences University Magna Graecia of Catanzaro, Catanzaro, Italy; Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy. Electronic address: rserra@unicz.it.

BACKGROUND Chronic Venous Disease (CVD) has a high prevalence in the western world. Varicose veins (VVs) are the main signs of this disease that is characterized by important pathological vessel wall changes. The aim of this study is to correlate the main histopathological abnormalities with related clinical issues of CVD. METHODS A cohort of patients with VVs scheduled for open surgical treatment namely stab avulsion of VVs was recruited. Subsequently, venous tissue from stab avulsion was collected in order to evaluate the following biomarkers: Vascular-Endothelial Growth Factor (VEGF), Protein Gene Product 9.5 (PGP 9.5), Fibronectin (FN), and Matrix Metalloproteinase-9 (MMP-9). The Clinical-Etiology-Anatomy-Pathophysiology (CEAP) criteria were used to classify CVD. RESULTS Fourteen tissue fragments were processed for histological and immunohistochemical studies. Of these, 43% were from CEAP C2 patients, 36% from CEAP C3 patients, and 21% from CEAP C4 patients. CEAP Class C2 had few to moderate structures positive to VEGF; occasional structures positive to Fibronectin, numerous structures positive to MMP9, few to moderate structures positive to PGP 9.5. CEAP Class C3 had moderate structures positive to VEGF; few to moderate structures positive to Fibronectin; many structures positive to MMP9; few to moderate structures positive to PGP 9.5. CEAP Class C4 had numerous structures positive to VEGF; numerous structures positive to Fibronectin; abundant structures positive to MMP-9; few structures positive to PGP 9.5. CONCLUSIONS In this study, positive VEGF, FN, and MMP-9 structures were found with increasing trends in relation to the disease staging. VEGF and FN are associated with a progressive increase from C2 to C4. The MMP-9 marker has an important positivity even at early stage of the disease, being higher in CEAP C4 patients. PGP 9.5 decreases in CEAP C4 patients and this is concordant to decreased vein wall innervation.

UI MeSH Term Description Entries
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014648 Varicose Veins Enlarged and tortuous VEINS. Varices,Varix,Varicose Vein,Vein, Varicose,Veins, Varicose
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
January 1972, Cardiovascular clinics,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
December 1992, Circulation,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
February 2006, The Journal of cardiovascular surgery,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
January 2015, Journal of medicine and life,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
March 2021, Medicina (Kaunas, Lithuania),
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
September 1995, Stroke,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
January 2009, Transplantation proceedings,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
January 1973, Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
January 1973, ZWR,
Raffaele Serra, and Umberto Marcello Bracale, and Caterina Chilà, and Maria Renne, and Chiara Mignogna, and Nicola Ielapi, and Salvatore Ciranni, and Giuseppina Torcia, and Egidio Bevacqua, and Maria Donata Di Taranto, and Pasquale Mastroroberto, and Giuseppe Filiberto Serraino, and Michele Provenzano, and Michele Andreucci
July 2006, European journal of endocrinology,
Copied contents to your clipboard!